Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
22
INM Quote, Financials, Valuation and Earnings
Last price:
$1.05
Seasonality move
:
14.22%
Day range:
$1.03 - $1.12
52-week range:
$1.03 - $8.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.43x
P/B ratio:
0.26x
Volume:
184.4K
Avg. volume:
657.4K
1-year change:
-77.64%
Market cap:
$3M
Revenue:
$4.9M
EPS (TTM):
-$6.91
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INM
InMed Pharmaceuticals, Inc.
|
$1.5M | -- | 44.01% | -- | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$74.7M | $0.22 | 24.77% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
LEXX
Lexaria Bioscience Corp.
|
$100K | -- | -42.53% | -- | $4.50 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.06 | -- | -13.85% | $5.55 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.20 | -- | -43.57% | $55.40 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INM
InMed Pharmaceuticals, Inc.
|
$1.06 | -- | $3M | -- | $0.00 | 0% | 0.43x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$15.95 | $16.67 | $2.1B | 28.43x | $0.00 | 0% | 8.47x |
|
EDSA
Edesa Biotech, Inc.
|
$1.42 | $11.00 | $10M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$0.62 | $4.50 | $15.4M | -- | $0.00 | 0% | 15.74x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.87 | $5.55 | $94M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$44.82 | $55.40 | $3.5B | -- | $0.00 | 0% | 471.02x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INM
InMed Pharmaceuticals, Inc.
|
5.23% | 1.215 | 11.23% | 6.25x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.204 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -1.109 | -- | 10.60x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -0.522 | 0.6% | 3.11x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.553 | 0.41% | 1.61x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | -0.090 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INM
InMed Pharmaceuticals, Inc.
|
$246.5K | -$1.8M | -80.72% | -88.06% | -157.46% | -$1.6M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.9K | -$2.5M | -77.45% | -77.48% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
InMed Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns INM or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -154.17% compared to InMed Pharmaceuticals, Inc.'s net margin of 42.95%. InMed Pharmaceuticals, Inc.'s return on equity of -88.06% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital INMInMed Pharmaceuticals, Inc.22.01% -$0.44 $12.2M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About INM or AUPH?
InMed Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 38524.54%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 4.49%. Given that InMed Pharmaceuticals, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe InMed Pharmaceuticals, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INMInMed Pharmaceuticals, Inc.0 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is INM or AUPH More Risky?
InMed Pharmaceuticals, Inc. has a beta of 0.328, which suggesting that the stock is 67.246% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.462, suggesting its more volatile than the S&P 500 by 46.187%.
-
Which is a Better Dividend Stock INM or AUPH?
InMed Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INM or AUPH?
InMed Pharmaceuticals, Inc. quarterly revenues are $1.1M, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. InMed Pharmaceuticals, Inc.'s net income of -$1.7M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, InMed Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 28.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMed Pharmaceuticals, Inc. is 0.43x versus 8.47x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INMInMed Pharmaceuticals, Inc.0.43x -- $1.1M -$1.7M AUPHAurinia Pharmaceuticals, Inc.8.47x 28.43x $73.5M $31.6M
-
Which has Higher Returns INM or EDSA?
Edesa Biotech, Inc. has a net margin of -154.17% compared to InMed Pharmaceuticals, Inc.'s net margin of --. InMed Pharmaceuticals, Inc.'s return on equity of -88.06% beat Edesa Biotech, Inc.'s return on equity of -77.48%.
Company Gross Margin Earnings Per Share Invested Capital INMInMed Pharmaceuticals, Inc.22.01% -$0.44 $12.2M EDSAEdesa Biotech, Inc.-- -$0.32 $12.5M -
What do Analysts Say About INM or EDSA?
InMed Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 38524.54%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 674.65%. Given that InMed Pharmaceuticals, Inc. has higher upside potential than Edesa Biotech, Inc., analysts believe InMed Pharmaceuticals, Inc. is more attractive than Edesa Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INMInMed Pharmaceuticals, Inc.0 0 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is INM or EDSA More Risky?
InMed Pharmaceuticals, Inc. has a beta of 0.328, which suggesting that the stock is 67.246% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.133, suggesting its less volatile than the S&P 500 by 86.677%.
-
Which is a Better Dividend Stock INM or EDSA?
InMed Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INM or EDSA?
InMed Pharmaceuticals, Inc. quarterly revenues are $1.1M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. InMed Pharmaceuticals, Inc.'s net income of -$1.7M is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, InMed Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMed Pharmaceuticals, Inc. is 0.43x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INMInMed Pharmaceuticals, Inc.0.43x -- $1.1M -$1.7M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns INM or LEXX?
Lexaria Bioscience Corp. has a net margin of -154.17% compared to InMed Pharmaceuticals, Inc.'s net margin of -2178.51%. InMed Pharmaceuticals, Inc.'s return on equity of -88.06% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital INMInMed Pharmaceuticals, Inc.22.01% -$0.44 $12.2M LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About INM or LEXX?
InMed Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 38524.54%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $4.50 which suggests that it could grow by 629.34%. Given that InMed Pharmaceuticals, Inc. has higher upside potential than Lexaria Bioscience Corp., analysts believe InMed Pharmaceuticals, Inc. is more attractive than Lexaria Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings INMInMed Pharmaceuticals, Inc.0 0 0 LEXXLexaria Bioscience Corp.1 0 0 -
Is INM or LEXX More Risky?
InMed Pharmaceuticals, Inc. has a beta of 0.328, which suggesting that the stock is 67.246% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.631, suggesting its less volatile than the S&P 500 by 36.888%.
-
Which is a Better Dividend Stock INM or LEXX?
InMed Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INM or LEXX?
InMed Pharmaceuticals, Inc. quarterly revenues are $1.1M, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. InMed Pharmaceuticals, Inc.'s net income of -$1.7M is higher than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, InMed Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMed Pharmaceuticals, Inc. is 0.43x versus 15.74x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INMInMed Pharmaceuticals, Inc.0.43x -- $1.1M -$1.7M LEXXLexaria Bioscience Corp.15.74x -- $174K -$2.7M
-
Which has Higher Returns INM or ONCY?
Oncolytics Biotech, Inc. has a net margin of -154.17% compared to InMed Pharmaceuticals, Inc.'s net margin of --. InMed Pharmaceuticals, Inc.'s return on equity of -88.06% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital INMInMed Pharmaceuticals, Inc.22.01% -$0.44 $12.2M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About INM or ONCY?
InMed Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 38524.54%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 535.12%. Given that InMed Pharmaceuticals, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe InMed Pharmaceuticals, Inc. is more attractive than Oncolytics Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INMInMed Pharmaceuticals, Inc.0 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is INM or ONCY More Risky?
InMed Pharmaceuticals, Inc. has a beta of 0.328, which suggesting that the stock is 67.246% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.717%.
-
Which is a Better Dividend Stock INM or ONCY?
InMed Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INM or ONCY?
InMed Pharmaceuticals, Inc. quarterly revenues are $1.1M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. InMed Pharmaceuticals, Inc.'s net income of -$1.7M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, InMed Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMed Pharmaceuticals, Inc. is 0.43x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INMInMed Pharmaceuticals, Inc.0.43x -- $1.1M -$1.7M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns INM or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -154.17% compared to InMed Pharmaceuticals, Inc.'s net margin of -867.29%. InMed Pharmaceuticals, Inc.'s return on equity of -88.06% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital INMInMed Pharmaceuticals, Inc.22.01% -$0.44 $12.2M XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About INM or XENE?
InMed Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 38524.54%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.40 which suggests that it could grow by 23.61%. Given that InMed Pharmaceuticals, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe InMed Pharmaceuticals, Inc. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INMInMed Pharmaceuticals, Inc.0 0 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is INM or XENE More Risky?
InMed Pharmaceuticals, Inc. has a beta of 0.328, which suggesting that the stock is 67.246% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 0.974, suggesting its less volatile than the S&P 500 by 2.579%.
-
Which is a Better Dividend Stock INM or XENE?
InMed Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INM or XENE?
InMed Pharmaceuticals, Inc. quarterly revenues are $1.1M, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. InMed Pharmaceuticals, Inc.'s net income of -$1.7M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, InMed Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMed Pharmaceuticals, Inc. is 0.43x versus 471.02x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INMInMed Pharmaceuticals, Inc.0.43x -- $1.1M -$1.7M XENEXenon Pharmaceuticals, Inc.471.02x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
